Cargando…
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Pat...
Autores principales: | Janzic, Urska, Bidovec-Stojkovic, Urska, Korosec, Peter, Mohorcic, Katja, Mrak, Loredana, Caks, Marina, Ravnik, Maja, Skof, Erik, Rijavec, Matija |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301109/ https://www.ncbi.nlm.nih.gov/pubmed/37376406 http://dx.doi.org/10.3390/vaccines11061017 |
Ejemplares similares
-
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
por: Janzic, Urska, et al.
Publicado: (2022) -
188P Efficacy of SARS-CoV-2 based mRNA vaccines for patients with thoracic malignancies with 6 months follow up: A prospective observational study
por: Janzic, U., et al.
Publicado: (2022) -
Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients
por: Šokić, Maruša Kopač, et al.
Publicado: (2022) -
Chemokines during anaphylaxis: the importance of CCL2 and CCL2-dependent chemotactic activity for basophils
por: Vantur, Romana, et al.
Publicado: (2020) -
Fatal Hymenoptera Venom–Triggered Anaphylaxis in Patients with Unrecognized Clonal Mast Cell Disorder—Is Mastocytosis to Blame?
por: Rijavec, Matija, et al.
Publicado: (2023)